Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| That said, we believe our ECO Synthesis manufacturing platform to enable the commercial scale manufacturer of RNAi therapeutics has true breakout potential to transform the value trajectory of Codexis |
| We ended 2023 strongly with clear indications that the strategic decisions we made last year are translating into real momentum |
| meeting in May, we've been very pleased with the performance of the ECO Synthesis manufacturing platform, which has been easily exceeding the sequence length previously achieved by completing enzymatic RNA synthesis technologies |
| If they asked us to come back and do it again, the economics here were really favorable in terms of a total return on investment with a couple of years of evolution to move on to a mid-single-digit million product for a deal |
| Kevin Norrett So I'll let Sri comment on some of the contribution in '24, but the feedback we've received from external parties and from the investment community is very positive in terms of the partnering aspect with Aldevron, they're a leader in the mRNA space and certainly can extend our commercial reach in this space that is growing with the HiCap RNA polymerase |
| Our enzyme engineering teams have made tremendous progress in transforming native enzymes into high-performance biocatalysts that together offer a scalable process solution for siRNA manufacturing |
| Having the ability to license the ECO Synthesis manufacturing platform to large pharma and large CDMO customers, along with the ability to provide a complete solution for smaller pharma customers enhances our ability to win market share from different segments |
| Then with a double standard RNA ligase, that is a really exciting product because that's the same product we can - the program, we can sell to multiple customers where we were getting upfront enzyme payments and potentially royalties and significant supply agreements down there |
| Offering improved capping efficiency and reduced double-stranded RNA contamination, this enzyme represents a meaningful step up from the wild-type variant available on the market today |
| Sri will describe the financial details in his comments, but the punch line is that the Innovatus deal fully funds the construction and operation of our ECO Synthesis Innovation Lab several years and strengthens our balance sheet and increases our operational flexibility through our projected runway to cash flow positivity around the end of 2026 |
| This facility will put us in the best position possible to drive rapid uptake of our ECO Synthesis manufacturing platform, and we're pleased to have secured the capital to get it up and running for the next few years |
| Finally, we added more strength to our balance sheet just over the last few days when we announced the completion of an exclusive out license for a noncore asset this time with Roche for our newly engineered double-stranded DNA ligase |
| As a result, we now have projected runway through positive cash flow expected around the end of 2026, an innovation engine with an anticipated billion-dollar-plus market potential in our ECO Synthesis manufacturing platform and an adjacent growing core pharmaceutical manufacturing business that generates cash and boosts our relevant commercial reach |
| For Aldevron, this product is compelling from both a scientific and commercial perspective and they can maximize its value given their existing footprint in the mRNA manufacturing arena |
| We believe Codexis is uniquely equipped to meet that challenge because we've been doing something extremely similar for a decade or more through our pharmaceutical manufacturing business |
| From our standpoint, Aldevron offered strong terms and a rapid path to manufacturing a GMP version of this enzyme |
| With a greatly reduced burn rate, a growing base business grounded in solid customers and a disruptive platform with enormous potential upside, Codexis has all the components in place to become a breakout story, and I encourage you to stay tuned for an exciting year ahead |
| Finally, I'm thrilled that we anticipate offering a near-term solution to our future potential ECO Synthesis manufacturing platform customers with our double-stranded ecoRNA ligase, which we plan to make available for customers in the second half of this year |
| This is - this was a really exciting deal for us |
| When you take a step back, the progress we've made with the ECO Synthesis platform over the past year seems quite remarkable |
| And today, we're pleased to highlight anticipated 2024 product revenue growth of at least 10% from 2023 |
| And I'm really excited because the ECO Synthesis Innovation Lab provides us the blueprint for the potential future production of GMP-grade siRNA |
| These examples demonstrate our ability to find partners who can extend our commercial reach and to monetize high-value assets that are noncore to our business |
| Before we dive into the fourth quarter and full year 2023 financials, I'd like to reiterate Stephen's commentary on the recent loan agreement with Innovatus on Slide 11, between the rapid technical progress we've made with the ECO Synthesis manufacturing platform and the increased commercial engagement we've seen, this is the right time to accelerate our technology's value creation |
| The great thing about Codexis is the synergy of the experience and commercial infrastructure of our pharmaceutical manufacturing business with the emerging opportunity of the ECO Synthesis manufacturing platform |
| First, driven by the extremely encouraging technical progress we're making with the ECO Synthesis manufacturing platform that Stefan Lutz will describe later in this call, we announced plans to initiate the construction schedule for our ECO Synthesis Innovation Lab |
| Given Aldevron's leadership in mRNA manufacturing and the evolving RNA manufacturing landscape, this is a valuable relationship to cultivate |
| With regards to 2025 and beyond, we're expecting them to move into a GMP version, where it's also a very healthy royalty associated with that from a product revenue standpoint |
| Since then, as Stephen noted, we have completed an exciting series of deals and announcements, and I view our consistent execution as confirmation that we are focusing our efforts on the right assets |
| We expect that this facility will be a hugely valuable resource to support the technical and commercial advancement of our ECO Synthesis manufacturing platform |
| Statement |
|---|
| We were focused on that aspect because we're exiting the genomics business, and we really have a lack of control in terms of their product cycle, and we learned that from the Evo T4 experience |
| As a result, our sense of future demand comes down to active customer communication and overall market model |
| One of the things that the ECO Innovation Lab really offers now is the ability to hit this small and medium-sized pharma segment that was going to be difficult because they wanted a path from preclinical all the way through to GMP |
| This was also our lowest quarter of cash burn, consistent with our expectations following the decision to streamline our portfolio and consolidate facilities last year |
| As a result, looking ahead, we expect a reduced concentration in our 2024 product revenue base |
| I would have some connection difficulties |
| While R&D revenues are down year-over-year, it's important to note that 2023 R&D revenues included $6.1 million for biotherapeutics business and $7 million in noncash revenue related to Pfizer applying a portion of their retainer fee credit to a new program |
| While we expect annual product revenue growth to be sustainable, all of these factors contribute to why quarter-over-quarter product revenue tends to be unpredictable |
| We expect that base to actually come down a bit, but then be offset by some incremental investments in ECO, including in the ECO lab later this year |
| The last two decades of experience have taught us that the solution to a difficult challenge sometimes lies in evolving the enzyme and sometimes in tweaking the reaction conditions |
| To help with modeling, based on our current visibility to the timing of customer orders, we expect our revenues will be weighted towards the second half of the year, with Q2 anticipated to be our lowest quarter of the year |
| You got phosphoramidite chemistry gets very inefficient in the longer strands of siRNA over time |
| Remember, this has a significant impact in terms of cost reduction |
Please consider a small donation if you think this website provides you with relevant information